MYCure, by Peptomyc

Innovative cancer therapy through Myc inhibition

Cancer is a global challenge with 9 million deaths annually and new cases projected to rise by 70% in the next 20 years. There is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2M new cases in the last year, accounting for approximately 20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic.

Our client, the company Peptomyc, is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapy inhibiting Myc. Myc is a transcription factor that controls growth, survival and microenvironment of tumour cells and is deregulated in many tumour types, but has until now resisted efforts to develop effective inhibitors. Peptomyc, with its patented OMO-103 product, is able to penetrate nuclei, attack Myc and kill cancer cells.

With the intention of bringing their fantastic product to the market, Peptomyc submitted their proposal to the April call of the SME Instrument Phase 2 and we are very pleased to announce that they have obtained the necessary grant to carry out their project.

It is a great satisfaction for Aristos to have helped Peptomyc achieve this success and we wish them all the luck in the world so that they can save thousands and thousands of lives in the near future.